Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD22. The page also collects GeneMedi's different modalities and formats products for CD22 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD22 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022]

Target IDGM-T37539
Target NameCD22
Gene ID933
Gene Official NameCD22
Gene AliasSIGLEC-2, SIGLEC2
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made CD22-specific INN-index biosimilar (antibody&conjugates)-Moxetumomab, inotuzumab ozogamicin, Inotuzumab, pinatuzumab vedotin, Epratuzumab, bectumomab, Pinatuzumab, Suciraslimab, moxetumomab pasudotox

Anti-CD22 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-358Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibodyMoxetumomabCD22Fv FusionINN mab
GMP-Bios-INN-868Pre-Made Inotuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugateinotuzumab ozogamicinCD22Whole mAb ADCINN mab
GMP-Bios-ab-275Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibodyInotuzumabCD22Whole mAb ADCINN mab
GMP-Bios-INN-960Pre-Made Pinatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugatepinatuzumab vedotinCD22Whole mAb ADCINN mab
GMP-Bios-ab-190Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibodyEpratuzumabCD22Whole mAbINN mab
GMP-Bios-INN-751Pre-Made Bectumomab Biosimilar, Fab Fusion, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibodybectumomabCD22Fab FusionINN mab
GMP-Bios-ab-444Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibodyPinatuzumabCD22Whole mAb ADCINN mab
GMP-Bios-ab-697Pre-Made Suciraslimab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibodySuciraslimabCD22Whole mAbINN mab
GMP-Bios-INN-920Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin Amoxetumomab pasudotoxCD22Fusion ProteinINN mab



Pre-made anti-CD22 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD22 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD22 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T37539-AbAnti-CD22 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×